Description
Product details
TRIGLICLAGLAZE 30 Gliclazide (SR) Pioglitazone and Metformin HCL (SR) TRIGLICLAGLAZE 30 is a combination medication formulated to manage type 2 diabetes mellitus effectively. It combines three key components: Gliclazide (SR), Pioglitazone, and Metformin HCI (SR), each targeting different aspects of glucose regulation to achieve optimal blood sugar control. Gliclazide (SR): Gliclazide is a sulfonylurea medication that works by stimulating the pancreas to release insulin, which helps lower blood sugar levels. The sustained-release (SR) formulation ensures a gradual and prolonged release of the medication, providing consistent glucose-lowering effects throughout the day. Pioglitazone: Pioglitazone belongs to the thiazolidinedione class of drugs and enhances insulin sensitivity in muscle and fat tissues. By improving the body's response to insulin, Pioglitazone helps reduce insulin resistance and promotes better glucose utilization by cells. Metformin HCI (SR): Metformin is a biguanide medication that works primarily by reducing glucose production in the liver and increasing insulin sensitivity in peripheral tissues. The sustained-release formulation ensures a gradual release of Metformin, minimizing gastrointestinal side effects and providing extended blood sugar control. Key Benefits of TRIGLICLAGLAZE 30: Comprehensive Glucose Control: The combination of Gliclazide (SR), Pioglitazone, and Metformin HCI (SR) targets multiple pathways involved in glucose metabolism. This comprehensive approach helps achieve better overall blood sugar control throughout the day. Stimulates Insulin Release: Gliclazide stimulates insulin secretion from the pancreas, especially after meals, which is crucial for managing postprandial (after-meal) glucose spikes. Improves Insulin Sensitivity: Pioglitazone enhances insulin sensitivity in muscle and fat tissues, allowing for better glucose uptake and utilization by cells. This action helps reduce insulin resistance, a hallmark of type 2 diabetes. Reduces Hepatic Glucose Production: Metformin HCI (SR) reduces the production of glucose in the liver, helping to lower fasting blood sugar levels and prevent excessive glucose release into the bloodstream. Extended Blood Sugar Control: The sustained-release formulations of Gliclazide and Metformin ensure a gradual and prolonged release of the medications, leading to consistent blood sugar control and minimizing the risk of hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) fluctuations. Dosage and Administration: TRIGLICLAGLAZE 30 is typically taken orally once or twice daily, as prescribed by a healthcare provider. The medication is often taken with meals to reduce the risk of gastrointestinal side effects. Dosage adjustments may be necessary based on blood sugar levels and individual response to treatment. Follow your doctor's instructions carefully. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP: 7877551268, 7849827488 Order Now https://www.sterisonline.com/product/trigliclaglaze-30-134278
